Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06585241 · ClinicalTrials.gov registry record · Phase 4
A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine Formulations
A Phase 4 study of SARS-CoV-2, sponsored by ModernaTX.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 1,094
- Enrollment target
- 6
- Study locations
NCT06585241 is a Phase 4 study of SARS-CoV-2 that is actively recruiting participants, run by ModernaTX. The registered enrollment target is 1,094 participants, below the 3,731-participant average among 28 other SARS-CoV-2 trials with a reported enrollment target (71% lower). The trial reports 6 study locations across 5 states.
The verdict
NCT06585241, a Phase 4 study of SARS-CoV-2, is actively recruiting participants, sponsored by ModernaTX.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 1,094 participants
- Enrollment target
- 6
- Study locations
Study Summary
The purpose of this study is to investigate the immunogenicity and safety of mRNA COVID-19 variant-containing vaccine formulations against the vaccine-matched variants and newly emerged variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Conditions Studied
Interventions
- BIOLOGICAL mRNA-1273 Variant-containing Formulation
Study Locations (6)
Georgia
- CenExel - Atlanta
- CenExel - Decatur
Louisiana
- Velocity Clinical Research - Baton Rouge
Mississippi
- Velocity Clinical Research - Gulfport
Nebraska
- Velocity Clinical Research - Omaha
Virginia
- Richard Bennett - Clinical Research Partners - Richmond
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,094 participants |
| Start Date | 2024-09-09 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06585241
The ClinicalTrials.gov registry entry for NCT06585241 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 1,094 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,731-participant average among 28 other SARS-CoV-2 trials with a reported enrollment target (71% lower). The listed sponsor is ModernaTX, which has 90 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with SARS-CoV-2 appearing as the primary indexed condition, and to 1 intervention - of which mRNA-1273 Variant-containing Formulation is the first listed.
NCT06585241 reports 6 study locations spanning 5 distinct geographic areas - top geographies include Georgia, Louisiana, Mississippi.
Frequently Asked Questions
What is clinical trial NCT06585241 about?
NCT06585241 is a clinical study titled "A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine Formulations". The purpose of this study is to investigate the immunogenicity and safety of mRNA COVID-19 variant-containing vaccine formulations against the vaccine-matched variants and newly emerged variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
What is the current status of trial NCT06585241?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 1,094 participants. The study started on 2024-09-09. Estimated completion is 2026-12-31.
What conditions does trial NCT06585241 study?
This clinical trial studies the following conditions: SARS-CoV-2.
What interventions are being tested in trial NCT06585241?
The interventions under investigation include: mRNA-1273 Variant-containing Formulation (BIOLOGICAL).
Who is sponsoring clinical trial NCT06585241?
This trial is sponsored by ModernaTX, which has 90 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06585241 being conducted?
This trial has 6 study locations across Georgia, Louisiana, Mississippi, Nebraska, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for SARS-CoV-2
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Years of Age Without High-Risk Conditions for Severe Coronavirus Disease 2019 (COVID-19)
RECRUITING · Phase 4
-
Improving the Collaborative Health of Minority COVID-19 Survivor and Carepartner Dyads
RECRUITING · NA
-
Determinants of SARS (Severe Acute Respiratory Syndrome)-COV2 (COVID-19) Persistence After Convalescence
RECRUITING
-
Kisspeptin to Quantify GnRH Neuronal Function in Health and Disease
RECRUITING · Phase 1
-
Use and Effectiveness of COVID-19 Vaccines Using State Vaccine Registries and Insurance Claims Data
ACTIVE NOT RECRUITING
-
COVID-19 Biorepository
ACTIVE NOT RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.